An interventional study of Questionnaire and Physical Exam in Diabetes Mellitus and Psychological Distress, sponsored by Centre Hospitalier Universitaire de Nice. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Centre Hospitalier Universitaire de Nice · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 352 studies in Diabetes Mellitus with a site in France — 47 open to participants now, 53 under way, 3 of them phase 3. Diabetes Mellitus · France.
Among the 352 studies in Diabetes Mellitus with a site in France, this one is the 120th largest by enrollment of the 242 interventional ones that give a count, is one of 11 that started in 2026, is one of 100 with no phase, and was the 340th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →47 of the 352 studies in Diabetes Mellitus with a site in France are open now. Recruiting first, the newest first:
Nantes University Hospital · Sites in France
Ages 18–80
Pfizer · Sites in France, United States, Brazil and 8 more countries
Ages 18+
Centre Hospitalier Sud Francilien · Sites in France
Ages 18+
University Hospital, Grenoble · Sites in France
Ages 18+
Insulet Corporation · Sites in France
Ages 2+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
352 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 32 · Phase 3 83 · Phase 4 27
First in 1990; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 190 is above the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.
Median enrollment 187 across the 242 interventional studies, 268 across the 110 observational. Of the 263 that completed or were terminated, 71 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
144 of 352 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire de Nice is the lead sponsor of 725 studies on the registry; 177 are open to participants now.
Centre Hospitalier Universitaire de Nice has 5 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
13 of the studies in Diabetes Mellitus with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07455994Centre Hospitalier Universitaire de Saint EtienneDysautonomia in Children With Type 1 Diabetes | 2026-12 |
| NCT05795582Centre Hospitalier Universitaire de NiceUpstroke Time Measured by Photoplethysmography | 2026-12-14 |
| NCT06782997CHU de ReimsPerformance of the Electroretinogram, Performed and Interpreted by an Advanced Practice Nurse, in the Screening for Diabetic Retinopathy. | 2026-12-17 |
| NCT06066801Assistance Publique - Hôpitaux de ParisBedside Bone Biopsy in Diabetic Foot Osteomyelitis | 2027-03 |
| NCT07910721SolsiusContinuous Monitoring of Plantar Temperature Variations Using Connected Insoles and a Mobile Application for Diabetic Foot. | 2027-04-10 |
Add all 13 to your calendar (.ics) → With an account.
Among the 352 studies in Diabetes Mellitus with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Diabetes-related distress is a psychological construct associated with poorer glycaemic control in people living with diabetes. In France, few data are available on this topic and none focus specifically on adults with type 2 diabetes. Diabetes-related distress is not mentioned in the current French national guidelines on the management of type 2 diabetes, whereas international societies such as the ADA and, more recently, the EASD now recommend its regular assessment.
This single-centre observational study conducted in the endocrinology department of Nice University Hospital aims to estimate the prevalence of severe diabetes-related distress in adults with type 2 diabetes receiving usual care, and to identify associated clinical, psychosocial and lifestyle factors. Participants complete validated self-report questionnaires (PAID-20 for diabetes distress, WHOQOL-BREF for quality of life, and a modified Starting The Conversation dietary questionnaire), and clinical data are extracted from electronic medical records. The study does not modify usual medical management and participation consists only in completing the questionnaires and receiving feedback on the results.
The criteria were revised on the registry on Oct 28, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: Questionnaire and Physical Exam
Patients will be asked to complete questionnaires.
Prevalence of severe diabetes-related distress (PAID-20 score ≥ 40)
Diabetes-related distress will be assessed using the Problem Areas In Diabetes scale (PAID-20). The PAID-20 includes 20 items scored from 0 to 4; the total raw score (0-80) is multiplied by 1.25 to obtain a total score ranging from 0 to 100, with higher scores indicating greater diabetes-related distress. Severe diabetes-related distress is defined as a PAID-20 total score ≥ 40. The primary endpoint is the proportion of participants with PAID-20 ≥ 40.
Time frame: Baseline (single assessment during usual care visit, within 3 days from inclusion)
Prevalence of severe diabetes-related distress by care setting (ambulatory vs hospitalized)
Using the PAID-20 total score (0-100; higher scores indicate greater distress, severe distress defined as ≥ 40), the proportion of participants with severe diabetes-related distress will be calculated in two predefined subgroups: ambulatory patients (outpatient clinic and day hospital) and hospitalized patients (conventional hospitalization in endocrinology).
Time frame: Baseline (single assessment during usual care visit, within 3 days from inclusion)
Factors associated with diabetes-related distress (PAID-20 score)
The PAID-20 total score (0-100; higher scores indicate greater diabetes-related distress) will be analysed as a continuous variable. Decision-tree models (CHAID/CRT) will be used to explore associations between diabetes-related distress and predefined clinical, psychosocial and lifestyle variables.
Time frame: Baseline (single assessment during usual care visit, within 3 days from inclusion)
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Apr 2026 to primary completion in Oct 2026, 6 months.
Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 6 months is below that.
Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Jan 2027 → Oct 2026 and completion Jan 2027 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Nice →